CA2444013A1 - Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof - Google Patents
Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof Download PDFInfo
- Publication number
- CA2444013A1 CA2444013A1 CA002444013A CA2444013A CA2444013A1 CA 2444013 A1 CA2444013 A1 CA 2444013A1 CA 002444013 A CA002444013 A CA 002444013A CA 2444013 A CA2444013 A CA 2444013A CA 2444013 A1 CA2444013 A1 CA 2444013A1
- Authority
- CA
- Canada
- Prior art keywords
- combination
- inhibitor
- treatment
- gelatinise
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention concerns combinations of a gelatinase inhibitor, e.g. Ro-28-2653 with a cytotoxic/cytostatic agent and its use for the treatment of tumors.
Description
Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof The present invention relates to composition and methods for the treatment of patients with solid metastasized or non-metastasized tumors. These are characterized by administration of a gelatinase inhibitor, e.g. R0 28-2653 in combination with a cytotoxic/cytostatic compound, e.g. Cisplatin, Paclitaxel, Gemcitabine or Etoposide.
Introduction In modern clinical oncology, the biggest challenge for the successful treatment of patients is the problem of metastasis rather than the primary tumor itself.
For tumor cells to be able to spread and form distant metastases several prerequisites have to be fulfilled. Among these one of the most important ones is the ability to grow invasively into the surrounding tissue, intravasate into the blood- or lymphatic vessel system and finally to extravasate and seed in the target tissue.
Recently a new class of molecules, namely the proteases, were identified to play a major role in this process. With the help of these enzymes tumor cells break down extracellular matrix proteins which are major constituents of connective tissue and basal membranes. Among these proteases the matrix metalloproteases (MMPs), and, more specifically, MMP-2 and MMP-9 (= gelatinases A and B) were identified as major contributors in this process of matrix degradation (Johansson et al., Cell.
Mol. Life Sci. 57 (2000) 5-15). In addition, especially MMP-9 was found to play an important role in the formation of new blood vessels, a process called angiogenesis, which is essential for a tumor to establish and uphold a sufficient supply with nutrients and oxygen (Vu, T.H., et al., Cell 93 (1998) 411-422). Not surprisingly, indeed MMP-2 and/or MMP-9 were found to be overexpressed by a large proportion of individual tumors irrespective of histological origin.
Inhibition of MMPs, either with the naturally occurring Tissue Inhibitors of Metalloproteases (TIMPs), or with low molecular weight inhibitors, resulted in impressive anti-tumor and anti-metastatic effects in animal models (Brown, P.D., Medical Oncology 14 (1997) 1-10). Most of the low-molecular weight inhibitors of MMPs are derived from the hydroxamic acid compound class and inhibit MMPs in a broad manner, being not selective for MMP-2 and MMP-9, the lcey MMPs in tumor invasion, metastatic spread, and angiogenesis. However, MMP inhibiting molecules from various other structural classes, e.g. the tri-oxo pyrimidines, have been described, e.g. in WO 97/23465 and WO 01/25217, which are incorporated by reference. A member of this class of compounds, RO 28-2653, is an extremely potent, and highly selective, gelatinase inhibitor with an almost exclusive specificity for MMP-2, MMP-9, and MT1-MMP, the enzyme activating MMP-2, while sparing most other members of the MMP family of proteases. Ro 28-2653, with the chemical name 5-(4-biphenyl)-5-[N-(4-nitrophenyl) piperazinyl] barbituric acid is described in WO 97/23465.
Several MMP inhibitors, predominantly of the hydroxamic acid substance class were, and in part still are, in clinical testing. All of the published clinical results with these inhibitors were disappointing, showing little or no clinical efficacy (Fletcher, L., Nature Biotechnology 18 (2000) 1138-1139). The reason for this lack of efficacy in the clinic most likely is the fact that patients could not be given high enough doses for anti-tumor or anti-metastatic activity because of the side effects associated with these broadly acting inhibitors. These dose-limiting side effects were predominantly arthralgias and myalgias (Drumrnond, A.H., et al., Ann. N.Y.
Acad.
Sci. 878 (1999) 228-235). As a possible way to circumvent this problem, the combination of MMP inhibitors with classical cytostatic/cytotoxic compounds was evaluated in animal studies. Indeed, in these experiments, MMP inhibitors, in combination with cytostatic/cytotoxic drugs, showed enhanced efficacy (Giavazzi, R., et al., Clin. Cancer Res. 4 (1998) 985-992).
Ro 28-2653 is an MMP inhibitor with high selectivity for MMP-2 and MMP-9 and the treatment with this compound showed no side effects. Indeed, no side effects similar to those observed with the broad-spectrum inhibitors were seen in toxicological tests over a wide range of doses. Thus, no dose-limiting toxicities were expected with RO 28-2653, and accordingly no additional benefit from co-treatment with cytostaticlcytotoxic drugs was expected. However, to explore also the distant possibility of an additional benefit from combination treatment, such studies were initiated and conducted in various animal models. The models and cytostatic/cytotoxic drugs wexe chosen to reflect as broad a spectrum of ontological indications and clinically active treatment principles as possible.
Introduction In modern clinical oncology, the biggest challenge for the successful treatment of patients is the problem of metastasis rather than the primary tumor itself.
For tumor cells to be able to spread and form distant metastases several prerequisites have to be fulfilled. Among these one of the most important ones is the ability to grow invasively into the surrounding tissue, intravasate into the blood- or lymphatic vessel system and finally to extravasate and seed in the target tissue.
Recently a new class of molecules, namely the proteases, were identified to play a major role in this process. With the help of these enzymes tumor cells break down extracellular matrix proteins which are major constituents of connective tissue and basal membranes. Among these proteases the matrix metalloproteases (MMPs), and, more specifically, MMP-2 and MMP-9 (= gelatinases A and B) were identified as major contributors in this process of matrix degradation (Johansson et al., Cell.
Mol. Life Sci. 57 (2000) 5-15). In addition, especially MMP-9 was found to play an important role in the formation of new blood vessels, a process called angiogenesis, which is essential for a tumor to establish and uphold a sufficient supply with nutrients and oxygen (Vu, T.H., et al., Cell 93 (1998) 411-422). Not surprisingly, indeed MMP-2 and/or MMP-9 were found to be overexpressed by a large proportion of individual tumors irrespective of histological origin.
Inhibition of MMPs, either with the naturally occurring Tissue Inhibitors of Metalloproteases (TIMPs), or with low molecular weight inhibitors, resulted in impressive anti-tumor and anti-metastatic effects in animal models (Brown, P.D., Medical Oncology 14 (1997) 1-10). Most of the low-molecular weight inhibitors of MMPs are derived from the hydroxamic acid compound class and inhibit MMPs in a broad manner, being not selective for MMP-2 and MMP-9, the lcey MMPs in tumor invasion, metastatic spread, and angiogenesis. However, MMP inhibiting molecules from various other structural classes, e.g. the tri-oxo pyrimidines, have been described, e.g. in WO 97/23465 and WO 01/25217, which are incorporated by reference. A member of this class of compounds, RO 28-2653, is an extremely potent, and highly selective, gelatinase inhibitor with an almost exclusive specificity for MMP-2, MMP-9, and MT1-MMP, the enzyme activating MMP-2, while sparing most other members of the MMP family of proteases. Ro 28-2653, with the chemical name 5-(4-biphenyl)-5-[N-(4-nitrophenyl) piperazinyl] barbituric acid is described in WO 97/23465.
Several MMP inhibitors, predominantly of the hydroxamic acid substance class were, and in part still are, in clinical testing. All of the published clinical results with these inhibitors were disappointing, showing little or no clinical efficacy (Fletcher, L., Nature Biotechnology 18 (2000) 1138-1139). The reason for this lack of efficacy in the clinic most likely is the fact that patients could not be given high enough doses for anti-tumor or anti-metastatic activity because of the side effects associated with these broadly acting inhibitors. These dose-limiting side effects were predominantly arthralgias and myalgias (Drumrnond, A.H., et al., Ann. N.Y.
Acad.
Sci. 878 (1999) 228-235). As a possible way to circumvent this problem, the combination of MMP inhibitors with classical cytostatic/cytotoxic compounds was evaluated in animal studies. Indeed, in these experiments, MMP inhibitors, in combination with cytostatic/cytotoxic drugs, showed enhanced efficacy (Giavazzi, R., et al., Clin. Cancer Res. 4 (1998) 985-992).
Ro 28-2653 is an MMP inhibitor with high selectivity for MMP-2 and MMP-9 and the treatment with this compound showed no side effects. Indeed, no side effects similar to those observed with the broad-spectrum inhibitors were seen in toxicological tests over a wide range of doses. Thus, no dose-limiting toxicities were expected with RO 28-2653, and accordingly no additional benefit from co-treatment with cytostaticlcytotoxic drugs was expected. However, to explore also the distant possibility of an additional benefit from combination treatment, such studies were initiated and conducted in various animal models. The models and cytostatic/cytotoxic drugs wexe chosen to reflect as broad a spectrum of ontological indications and clinically active treatment principles as possible.
Surprisingly, combinations of RO 28-2653 with cytostatic/cytotoxic compounds in various models of different histological origin clearly showed enhanced anti-tumor activity as compared to the respective single-agent treatments. Thus, in principle all human patients with solid metastasized or non-metastasized tumors, e.g. tumors of the lung, prostate, colon, breast, pancreas, ovary, skin, kidney, bladder, liver, head and neck, stomach, and brain are eligible for treatment with gelatinase inhibitors in combination with cytotoxic/cytostatic compounds.
The treatment with the gelatinase-inhibitor most likely will be a chronic treatment, starting either simultaneously with the combination partner or sequentially, i.e.
before and after the treatment with the combination partner. In this context, simultaneous treatment means that the gelatinase inhibitor treatment takes place in parallel to, and is not stopped for, the necessary cycles of cytostatic/cytotoxic treatment, while sequential treatment means that the gelatinase inhibitor treatment is discontinued for the duration of the treatment with the cytostatic/cytotoxic drugs. The administration schedule depends on the tumor to be treated as well as on the cytostatic/cytotoxic agent to be used.
Preferred cytostatic/cytotoxic compounds are, for example: Cisplatin, Paclitaxel, Vinblastin, Mitomycin, Gerncitabine, Etoposide, Doxetaxel, Carboplatin, Irinotecan, Topotecan, Navelbine, Doxorubicin, Epirubicin, Oxaliplatin, 5 Fluoruracil, Capecitabine, 5-UFT, Herceptin, alpha interferon.
The administration of the gelatinase inhibitor will preferentially be oral, with doses ranging between 0.5 mg/kg and 50 mg/kg. Administration of the various combination partners will be as approved by the health authorities, which in most cases is by i.v. infusion. The partners used for the combination therapy can be contained in separate package format or together in a kit. Such a kit contains the i.v.
preparations of the cytotoxic/cytostatic agents, e.g. ampoules and blister packages with tablets of the gelatinase inhibitors.
The following experimental part, references and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
The treatment with the gelatinase-inhibitor most likely will be a chronic treatment, starting either simultaneously with the combination partner or sequentially, i.e.
before and after the treatment with the combination partner. In this context, simultaneous treatment means that the gelatinase inhibitor treatment takes place in parallel to, and is not stopped for, the necessary cycles of cytostatic/cytotoxic treatment, while sequential treatment means that the gelatinase inhibitor treatment is discontinued for the duration of the treatment with the cytostatic/cytotoxic drugs. The administration schedule depends on the tumor to be treated as well as on the cytostatic/cytotoxic agent to be used.
Preferred cytostatic/cytotoxic compounds are, for example: Cisplatin, Paclitaxel, Vinblastin, Mitomycin, Gerncitabine, Etoposide, Doxetaxel, Carboplatin, Irinotecan, Topotecan, Navelbine, Doxorubicin, Epirubicin, Oxaliplatin, 5 Fluoruracil, Capecitabine, 5-UFT, Herceptin, alpha interferon.
The administration of the gelatinase inhibitor will preferentially be oral, with doses ranging between 0.5 mg/kg and 50 mg/kg. Administration of the various combination partners will be as approved by the health authorities, which in most cases is by i.v. infusion. The partners used for the combination therapy can be contained in separate package format or together in a kit. Such a kit contains the i.v.
preparations of the cytotoxic/cytostatic agents, e.g. ampoules and blister packages with tablets of the gelatinase inhibitors.
The following experimental part, references and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.
_4_ Description of the Figures Figure 1 shows the effect of the combination of RO 28-2653 and Cisplatin on survival in the orthotopic HOC-22 ovarian cancer xenograft model. DDP = Cisplatin. Survival is displayed as Kaplan-Meyer-Plot. Statistics was calculated using the log rank test. Animals were treated with RO 28-2653 for three weeks, from day 7 to day 21, with daily oral doses of 45 mg/kg six times a week. Cisplatin treatment consisted of 4 doses of 3 mg/kg i.v. per mouse once every 4 days, starting on day 7.
Figure 2 shows the effect of the combination of RO 28-2653 and Paclitaxel on primary tumor size in the subcutaneous HCTII6 CL5.5 colon cancer xenograft model.
Figure 3 shows the effect of the combination of RO 28-2653 and Etoposide on the weight of primary tumors in the syngeneic orthotopic rat MatLyLu prostate cancer model. ~ Untreated Control ~ Vehicle Control ~ Etoposide ~ RO 28-2653 ~ RO 28-2653 + Etoposide.
- Mean tumor weight. Rats were treated with RO 28-2653 with daily oral doses of 100 mg/kg starting on day 6 after tumor implantation, until the penultimate day of the experiment (day 17). Etoposide was given intraperitoneally once daily, from day 6 to day I7, at a dose of 25 mg/m2.
Experimental Part Combination of RO 28-2653 with Cisplatin The activity of RO 28-2653 in combination with Cisplatin was evaluated in the human orthotopic ovarian carcinoma mouse xenograft model HOC-22. While control mice had a median survival time of 30 days, treatment with RO 28-2653 for three weeks, or Cisplatin for two weeks as single agents, resulted in an increase in lifespan of 63% and 95%, respectively. When used in combination, however, an increase in lifespan of 263% versus vehicle and 86% versus Cisplatin alone was observed (Fig. 1). Thus, RO 28-2653, when given in combination with Cisplatin, was able to potentiate its anti-tumor effect significantly and increase the survival time of the animals.
Combination of RO 28-2653 with Paclitaxel The activity of RO 28-2653 in combination with Paclitaxel was evaluated in the human subcutaneous colon carcinoma mouse xenograft model HCT 116 Cl 5.5 with primary tumor size as the endpoint. Animals from the Paclitaxel monotherapy group had an inhibition of primary tumor growth by 43% and 75% at the doses of 11.5 and 22.5 mg/kg, respectively. R0 28-2653 monotherapy resulted in the inhibition of primary tumor growth by 74% at the dose of 45 mg/kg. Combination therapy with both Paclitaxel and RO 28-2653 significantly inhibited primary tumor growth by 72% and 91% for the Paclitaxel doses of 11.5 and 22.5 mg/kg, respectively, with a dose of 45 g/kg for RO 28-2653 (Fig. 2). Thus, the combination treatment of RO 28-2653 with Paclitaxel resulted in a significant benefit for the experimental animals with respect to primary tumor size.
Combination of RO 28-2653 with Gemcitabine The activity of RO 28-2653 in combination with Gemcitabine was evaluated in the human orthotopic pancreas carcinoma mouse xenograft model PancTul with primary tumor size and number and size of metastases as endpoints. Animals from the Gemcitabine monotherapy group had an inhibition of primary tumor growth by 85%. R0 28-6253 monotherapy resulted in the inhibition of primary tumor growth by 66%. Importantly, combination therapy with both Gemcitabine and RO
28-2653 significantly inhibited primary tumor growth by 94% (Table 1). With respect to the number of metastases, in the untreated or vehicle treated control groups an average of 5.1 and 4.6 metastases per animal was found. While RO 28-2653 treatment reduced these numbers to an average of 2.5 metastases per animal, and Gemcitabine monotherapy to 0.4 metastases, combination treatment with Gemcitabine plus RO 28-2653 reduced this number even further to 0.08 metastases per animal (one single metastasis in the entire treatment group) (Table 2).
This is a further 5-fold reduction of the number of metastases beginning at an already low level, which makes this reduction even more impressive. This antimetastatic effect could be, at least in part, due to anti-angiogenic effects exerted by the gelatinase-inhibitor. In fact, a defect in neo-angiogenesis has been described for gelatinase B
defective mice, thus corroborating this hypothesis.
Table 1 No treatmentVehicle GemcitabineRo28-2653Gemcitabine 1 + 2 +
+ Vehicle+ VehicleRo28-2653 n=9 n=10 n=13 n=13 n=13 Tumor Primary9/9 10/10 13/13 13/13 13/13 take rate tumor Volume PrimaryVm=293079)Vm=333(87)Vm=51014)Vm=112046)Vm=2004) tumor mm3 mm3 mm3 mm3 mm3 NecrosisPrimary0/9 0/10 4/13 1/13 9/13 tumor Body m=-10 m=-11 (7)%m=-2 (+5)%m=-5 (4)%m=-1 (+5)% ~ (+4)%
wei ht Effect of the combination of RO 28-2653 and Gemcitabine on primary tumor volume in the orthotopic PancTul pancreas cancer xenograft model. Mice were treated with RO 28-2653 with daily oral doses of 45 mg/kg from day 7 until day 30.
Gemcitabine treatment consisted of one intraperitoneal dose of 2.2 mg/kg every second day from day 7 to day 30.
Table 2 No treatmentVehicle GemcitabineRo28-2653 Gemcitabine 1 + 2 + +
Vehicle + Vehicle Ro28-2653 n=9 n=10 n=13 n=13 n=13 Metastasis Lun / Mediastinum7/9 4110 0/13 2/13 0/13 Liver, 3/9 3/10 1/13 3/13 0113 in arench me Liver on 1/9 1/10 1/13 2/13 0/13 serosa Liver hilus1/9 2/13 0/13 4/13 0113 Kidneys/Adrenal4/9 3/10 0/13 1/13 0/13 land (ca sule) Spleen 3/9 3/10 0/13 0/13 0/13 (serosa).
gastrosplenic Ii ament Lymph nodes2/9 2/10 0/13 2/93 0113 in mesent Mesenten/ 1/9 0/10 0/13 0/13 0/13 < 3 metastasis(2 mm' ) Mesentery 7/9 7/10 0/13 5/13 0/13 metastasis(1-18 mm3 ) Ligament 5/g 3/10 0/13 0/13 0/13 of the uterus / testis (serosa), seminal vesicles Dia hra 3/9 5/10 0/13 3/13 0/13 m Pelvis 1/9 3/10 0/13 0/13 0/13 Site of surgical incision Small < 0/9 1/10 2/13 2/13 1/13 mm3 Medium 0/9 1/10 1/13 3/13 0/13__ < 50 mm3 Large 80-280g/g 8/10 0/13 6/13 ~ 0/13 mm Effect of the combination of RO 28-2653 and Gemcitabine on metastatic spread in the orthotopic PancTul pancreas cancer xenograft model. Mice were treated with 5 RO 28-2653 with daily oral doses of 45 mg/kg from day 7 until day 30.
Gemcitabine treatment consisted of one intraperitoneal dose of 2.2 mg/kg every second day from day 7 to day 30. o _g_ Combination of RO 28-2653 with Etoposide The activity of RO 28-2653 in combination with Etoposide was evaluated in the rat syngeneic orthotopic prostate carcinoma model MatLyLu with primary tumor size as endpoint. Animals from the Etoposide monotherapy group showed inhibition of primary tumor growth by 35% as compared to the vehicle-treated animals. R0 28-6253 monotherapy resulted in the inhibition of primary tumor growth by 86%.
Importantly, the combination therapy with both Etoposide and RO 28-2653 significantly inhibited primary tumor growth by 92% (Fig. 3).
List of References Brown, P.D., Medical Oncology 14 (1997) 1-10 Drummond, A.H., et al., Ann. N.Y. Acad. Sci. 878 ( 1999) 228-235 Fletcher, L., Nature Biotechnology 18 (2000) 1138-1139 Giavazzi, R., et al., Clin. Cancer Res. 4 (1998) 985-992 Johansson, N., et al., Cell. Mol. Life Sci. 57 (2000) 5-15 Vu, T.H., et al., Cell 93 ( 1998) 411-422
Figure 2 shows the effect of the combination of RO 28-2653 and Paclitaxel on primary tumor size in the subcutaneous HCTII6 CL5.5 colon cancer xenograft model.
Figure 3 shows the effect of the combination of RO 28-2653 and Etoposide on the weight of primary tumors in the syngeneic orthotopic rat MatLyLu prostate cancer model. ~ Untreated Control ~ Vehicle Control ~ Etoposide ~ RO 28-2653 ~ RO 28-2653 + Etoposide.
- Mean tumor weight. Rats were treated with RO 28-2653 with daily oral doses of 100 mg/kg starting on day 6 after tumor implantation, until the penultimate day of the experiment (day 17). Etoposide was given intraperitoneally once daily, from day 6 to day I7, at a dose of 25 mg/m2.
Experimental Part Combination of RO 28-2653 with Cisplatin The activity of RO 28-2653 in combination with Cisplatin was evaluated in the human orthotopic ovarian carcinoma mouse xenograft model HOC-22. While control mice had a median survival time of 30 days, treatment with RO 28-2653 for three weeks, or Cisplatin for two weeks as single agents, resulted in an increase in lifespan of 63% and 95%, respectively. When used in combination, however, an increase in lifespan of 263% versus vehicle and 86% versus Cisplatin alone was observed (Fig. 1). Thus, RO 28-2653, when given in combination with Cisplatin, was able to potentiate its anti-tumor effect significantly and increase the survival time of the animals.
Combination of RO 28-2653 with Paclitaxel The activity of RO 28-2653 in combination with Paclitaxel was evaluated in the human subcutaneous colon carcinoma mouse xenograft model HCT 116 Cl 5.5 with primary tumor size as the endpoint. Animals from the Paclitaxel monotherapy group had an inhibition of primary tumor growth by 43% and 75% at the doses of 11.5 and 22.5 mg/kg, respectively. R0 28-2653 monotherapy resulted in the inhibition of primary tumor growth by 74% at the dose of 45 mg/kg. Combination therapy with both Paclitaxel and RO 28-2653 significantly inhibited primary tumor growth by 72% and 91% for the Paclitaxel doses of 11.5 and 22.5 mg/kg, respectively, with a dose of 45 g/kg for RO 28-2653 (Fig. 2). Thus, the combination treatment of RO 28-2653 with Paclitaxel resulted in a significant benefit for the experimental animals with respect to primary tumor size.
Combination of RO 28-2653 with Gemcitabine The activity of RO 28-2653 in combination with Gemcitabine was evaluated in the human orthotopic pancreas carcinoma mouse xenograft model PancTul with primary tumor size and number and size of metastases as endpoints. Animals from the Gemcitabine monotherapy group had an inhibition of primary tumor growth by 85%. R0 28-6253 monotherapy resulted in the inhibition of primary tumor growth by 66%. Importantly, combination therapy with both Gemcitabine and RO
28-2653 significantly inhibited primary tumor growth by 94% (Table 1). With respect to the number of metastases, in the untreated or vehicle treated control groups an average of 5.1 and 4.6 metastases per animal was found. While RO 28-2653 treatment reduced these numbers to an average of 2.5 metastases per animal, and Gemcitabine monotherapy to 0.4 metastases, combination treatment with Gemcitabine plus RO 28-2653 reduced this number even further to 0.08 metastases per animal (one single metastasis in the entire treatment group) (Table 2).
This is a further 5-fold reduction of the number of metastases beginning at an already low level, which makes this reduction even more impressive. This antimetastatic effect could be, at least in part, due to anti-angiogenic effects exerted by the gelatinase-inhibitor. In fact, a defect in neo-angiogenesis has been described for gelatinase B
defective mice, thus corroborating this hypothesis.
Table 1 No treatmentVehicle GemcitabineRo28-2653Gemcitabine 1 + 2 +
+ Vehicle+ VehicleRo28-2653 n=9 n=10 n=13 n=13 n=13 Tumor Primary9/9 10/10 13/13 13/13 13/13 take rate tumor Volume PrimaryVm=293079)Vm=333(87)Vm=51014)Vm=112046)Vm=2004) tumor mm3 mm3 mm3 mm3 mm3 NecrosisPrimary0/9 0/10 4/13 1/13 9/13 tumor Body m=-10 m=-11 (7)%m=-2 (+5)%m=-5 (4)%m=-1 (+5)% ~ (+4)%
wei ht Effect of the combination of RO 28-2653 and Gemcitabine on primary tumor volume in the orthotopic PancTul pancreas cancer xenograft model. Mice were treated with RO 28-2653 with daily oral doses of 45 mg/kg from day 7 until day 30.
Gemcitabine treatment consisted of one intraperitoneal dose of 2.2 mg/kg every second day from day 7 to day 30.
Table 2 No treatmentVehicle GemcitabineRo28-2653 Gemcitabine 1 + 2 + +
Vehicle + Vehicle Ro28-2653 n=9 n=10 n=13 n=13 n=13 Metastasis Lun / Mediastinum7/9 4110 0/13 2/13 0/13 Liver, 3/9 3/10 1/13 3/13 0113 in arench me Liver on 1/9 1/10 1/13 2/13 0/13 serosa Liver hilus1/9 2/13 0/13 4/13 0113 Kidneys/Adrenal4/9 3/10 0/13 1/13 0/13 land (ca sule) Spleen 3/9 3/10 0/13 0/13 0/13 (serosa).
gastrosplenic Ii ament Lymph nodes2/9 2/10 0/13 2/93 0113 in mesent Mesenten/ 1/9 0/10 0/13 0/13 0/13 < 3 metastasis(2 mm' ) Mesentery 7/9 7/10 0/13 5/13 0/13 metastasis(1-18 mm3 ) Ligament 5/g 3/10 0/13 0/13 0/13 of the uterus / testis (serosa), seminal vesicles Dia hra 3/9 5/10 0/13 3/13 0/13 m Pelvis 1/9 3/10 0/13 0/13 0/13 Site of surgical incision Small < 0/9 1/10 2/13 2/13 1/13 mm3 Medium 0/9 1/10 1/13 3/13 0/13__ < 50 mm3 Large 80-280g/g 8/10 0/13 6/13 ~ 0/13 mm Effect of the combination of RO 28-2653 and Gemcitabine on metastatic spread in the orthotopic PancTul pancreas cancer xenograft model. Mice were treated with 5 RO 28-2653 with daily oral doses of 45 mg/kg from day 7 until day 30.
Gemcitabine treatment consisted of one intraperitoneal dose of 2.2 mg/kg every second day from day 7 to day 30. o _g_ Combination of RO 28-2653 with Etoposide The activity of RO 28-2653 in combination with Etoposide was evaluated in the rat syngeneic orthotopic prostate carcinoma model MatLyLu with primary tumor size as endpoint. Animals from the Etoposide monotherapy group showed inhibition of primary tumor growth by 35% as compared to the vehicle-treated animals. R0 28-6253 monotherapy resulted in the inhibition of primary tumor growth by 86%.
Importantly, the combination therapy with both Etoposide and RO 28-2653 significantly inhibited primary tumor growth by 92% (Fig. 3).
List of References Brown, P.D., Medical Oncology 14 (1997) 1-10 Drummond, A.H., et al., Ann. N.Y. Acad. Sci. 878 ( 1999) 228-235 Fletcher, L., Nature Biotechnology 18 (2000) 1138-1139 Giavazzi, R., et al., Clin. Cancer Res. 4 (1998) 985-992 Johansson, N., et al., Cell. Mol. Life Sci. 57 (2000) 5-15 Vu, T.H., et al., Cell 93 ( 1998) 411-422
Claims (7)
1. Use of a gelatinise inhibitor for the preparation of a medicament for the treatment of tumor growth or inhibiting metastases in combination with an antitumor agent.
2. Use according to claim 1, wherein the gelatinise inhibitor is 5-(4-biphenyl)-5-[N-(4-nitrophenyl) piperazinyl] barbituric acid.
3. Use according to claims 1 or 2, wherein the antitumor agent is a compound selected from the group consisting of Cisplatin, Paclitaxel, Vinblastin, Mitomycin, Gemcitabine, Etoposide, Doxetaxel, Carboplatin, Irinotecan, Topotecan, Navelbine, Doxorubicin, Epirubicin, Qxaliplatin, 5-Fluoruracil, Capecitabine, 5-UFT, Herceptin, alpha interferon
4. Use according to claims 1 to 3, whereby the gelatinise inhibitor and the tumor agent are administered simultaneously.
5. Use according to claims 1 to 3, whereby the gelatinise inhibitor and the tumor agent are administered sequentially.
6. Use according to claims 1 to 4, whereby the gelatinise inhibitor and the anti-tumor agent are part of a kit.
7. Use according to claims 1 to 6, wherein the gelatinise inhibitor is present as a tablet or capsule.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01110119 | 2001-05-03 | ||
| EP01110119.3 | 2001-05-03 | ||
| PCT/EP2002/004744 WO2002089824A1 (en) | 2001-05-03 | 2002-04-30 | Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2444013A1 true CA2444013A1 (en) | 2002-11-14 |
Family
ID=8177240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002444013A Abandoned CA2444013A1 (en) | 2001-05-03 | 2002-04-30 | Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040132739A1 (en) |
| EP (1) | EP1387689B1 (en) |
| JP (1) | JP2004527568A (en) |
| CN (1) | CN100338041C (en) |
| AT (1) | ATE344041T1 (en) |
| CA (1) | CA2444013A1 (en) |
| DE (1) | DE60215793T2 (en) |
| ES (1) | ES2274043T3 (en) |
| WO (1) | WO2002089824A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2440555A1 (en) | 2001-03-14 | 2002-09-19 | Bristol-Myers Squibb Company | Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases |
| RU2411043C2 (en) * | 2004-04-01 | 2011-02-10 | Юниверсите Де Льеж | Pharmaceutical compositions of pyrimidine-2, 4, 6-triones |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19548624A1 (en) * | 1995-12-23 | 1997-06-26 | Boehringer Mannheim Gmbh | New barbituric acid derivatives, processes for their preparation and medicaments containing these compounds |
| JP2002504916A (en) * | 1997-06-21 | 2002-02-12 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Barbituric acid derivatives with antimetastatic and antitumor activity |
| PA8469501A1 (en) * | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
| WO2000038715A2 (en) * | 1998-12-23 | 2000-07-06 | G.D. Searle & Co. | Use of an integrin antagonist and radiation in the treatment of neoplasia |
-
2002
- 2002-04-30 WO PCT/EP2002/004744 patent/WO2002089824A1/en active IP Right Grant
- 2002-04-30 EP EP02740542A patent/EP1387689B1/en not_active Expired - Lifetime
- 2002-04-30 DE DE60215793T patent/DE60215793T2/en not_active Expired - Fee Related
- 2002-04-30 JP JP2002586957A patent/JP2004527568A/en active Pending
- 2002-04-30 CN CNB028092430A patent/CN100338041C/en not_active Expired - Fee Related
- 2002-04-30 ES ES02740542T patent/ES2274043T3/en not_active Expired - Lifetime
- 2002-04-30 CA CA002444013A patent/CA2444013A1/en not_active Abandoned
- 2002-04-30 US US10/476,110 patent/US20040132739A1/en not_active Abandoned
- 2002-04-30 AT AT02740542T patent/ATE344041T1/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002089824A1 (en) | 2002-11-14 |
| US20040132739A1 (en) | 2004-07-08 |
| DE60215793D1 (en) | 2006-12-14 |
| EP1387689B1 (en) | 2006-11-02 |
| ATE344041T1 (en) | 2006-11-15 |
| ES2274043T3 (en) | 2007-05-16 |
| DE60215793T2 (en) | 2007-09-06 |
| CN100338041C (en) | 2007-09-19 |
| JP2004527568A (en) | 2004-09-09 |
| CN1505521A (en) | 2004-06-16 |
| EP1387689A1 (en) | 2004-02-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2767664C2 (en) | Combination therapy with anticancer alkaloid | |
| ES2661216T3 (en) | Combined method to treat cancer or a precancerous state | |
| RU2429838C2 (en) | Combined chemotherapy | |
| KR100718946B1 (en) | Effective antitumour treatments | |
| ES2235499T3 (en) | USE OF PROPIONIL L-CARNITINE AND L-CARNITINE OIL DERIVATIVES IN THE PREPARATION OF MEDICINES WITH ANTI-BANERIGAN ACTIVITY. | |
| JP2012515184A (en) | How to treat colorectal cancer | |
| EP2822558A2 (en) | Procaspase 3 activation by combination therapy | |
| JP2016503421A (en) | Inhibition of drug-resistant cancer cells | |
| TW201825084A (en) | Pharmaceutical combination for cancer treatment and therapeutic use thereof | |
| WO2009062135A1 (en) | Hsp90 inhibitors of protein-protein interaction hsp90 chaperone complexes and therapeutic uses thereof | |
| NZ537759A (en) | Combination of chemotherapeutic drugs for increasing antitumor activity | |
| EP1387689B1 (en) | Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof | |
| US20100240595A1 (en) | Improved Antitumoral Treatments | |
| Caraglia et al. | Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation | |
| AU2002314018A1 (en) | Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof | |
| RU2724341C1 (en) | Combined composition for preventing or treating cancer, containing benzophenone-thiazole derivatives as vda and topoisomerase inhibitor | |
| KR20120104574A (en) | Tivozanib and temsirolimus in combination | |
| WO2015144636A1 (en) | Methods for the treatment of t-cell acute lymphoblastic leukemias | |
| RU2284818C2 (en) | Combined chemotherapy | |
| KR100356374B1 (en) | A cough inhibitory composition containing iron showing inhibitory effects on cough associated with angiotensin converting enzyme inhibitors | |
| WO2019124423A1 (en) | Agent for progression suppression, treatment, prophylaxis and/or recurrence prevention of cancer | |
| CA3239676A1 (en) | Combination therapy comprising a pkc inhibitor and a c-met inhibitor | |
| AU2013230994B2 (en) | Procaspase 3 activation by combination therapy | |
| CA2472160A1 (en) | Quinazolinone compounds in combined modalities for improved cancer treatment | |
| JP2004514683A (en) | Simultaneous administration of levamisole and 5-fluorouracil |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |